Biotechnology

LAKESHORE BIOPHARMA CO LTD

Lakeshore Biopharma Co Ltd released FY2025 earnings on July 31 (EST), actual revenue USD 85.29 M (forecast USD 109.25 M), actual EPS USD -0.7237

Lakeshore Biopharma Co Ltd released FY2024 earnings on July 31 (EST), actual revenue USD 79.41 M (forecast USD 82.56 M), actual EPS USD -5.6139

Lakeshore Biopharma Co Ltd released FY2023 Annual Earnings on July 31, 2025 (EST), Actual Revenue: USD 99.49 M, Actual EPS: USD -3.4088

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

LSBCF

LakeShore Biopharma has amended its merger agreement with Oceanpine Skyline, reducing the per-share merger price from $0.90 to $0.066, while still offering a 46.7% premium over its recent closing price. The deal values LakeShore at approximately $2.7 million, with plans to delist from the OTC market. The agreement extends the termination date and lowers fees, backed by a shareholder group with 53.35% voting rights. Spark's analysis rates LSBCF as an Underperform due to ongoing losses and negative cash flow, despite some positive trends in gross margins.

Tip Ranks

LAKESHORE BIOPHARMA CO LTD C/WTS 15/03/2028 (TO PUR ORD)

LakeShore Biopharma

LakeShore Biopharma Slashes Merger Price in Amended Going-Private Deal

IBBQ

AMAM

LIXT

LABU

Lytix Biopharma Grants Share Options to Board Member Under Incentive Plan

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

iShares Global Healthcare

Protalix Biotherap

VG Health

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

iShares US Pharma

Ambrx Biopharma

ALPS Medical Breakthrough

Lixte Biotechnology

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Health Care Select Sector SPDR

Lytix Biopharma Grants Share Options to Board Member Under Incentive Plan

Argent BioPharma Shareholders Back Capital Moves at General Meeting

Bioxcel Therap

Argent BioPharma Shareholders Back Capital Moves at General Meeting

LSBWF

LakeShore Biopharma Weighs Cut‑Price Take‑Private Bid After RMB576.5 Million Arbitration Hit

LakeShore Biopharma Weighs Cut‑Price Take‑Private Bid After RMB576.5 Million Arbitration Hit

Lytix Biopharma Calls April AGM and Proposes No 2025 Dividend

Lytix Biopharma Calls April AGM and Proposes No 2025 Dividend

ABVC

Argent Biopharma Issues 2.5 Million Unquoted Performance Rights Under Incentive Scheme

ABVC BioPharma

Argent Biopharma Issues 2.5 Million Unquoted Performance Rights Under Incentive Scheme

LakeShore Biopharma has received a notice from a Buyer Group regarding a going-private transaction at $0.90 per share. The Buyer Group claims that recent arbitral awards resulting in a financial liability of approximately RMB576,500,000 constitute a "Company Material Adverse Effect," allowing them to withdraw from the merger. Consequently, the extraordinary general meeting scheduled for February 12, 2026, has been postponed. The Company will review the claims and provide updates as necessary.

prnewswire

07:00 ETLakeShore Biopharma Announces Receipt of Buyer Group Notice and Postponement of Extraordinary General Meeting of Shareholders

Lytix Biopharma AS has received shareholder approval for a NOK 30 million offering and will convert to a public limited liability company, changing its name to Lytix Biopharma ASA. The extraordinary general meeting also approved amendments to the articles of association, elected Darlene Deptula-Hicks to the board until 2027, and set the subscription period for the new share offering from January 27 to February 10, 2026. These actions aim to strengthen Lytix's capital base and governance as it advances its oncology pipeline.

Lytix Biopharma Wins Shareholder Backing for NOK 30m Offering and Conversion to Public Company

LAKESHORE BIOPHARMA CO LTD(LSBCF.US)

LakeShore Biopharma Slashes Merger Price in Amended Going-Private Deal

Lytix Biopharma Grants Share Options to Board Member Under Incentive Plan

Argent BioPharma Shareholders Back Capital Moves at General Meeting

LakeShore Biopharma Weighs Cut‑Price Take‑Private Bid After RMB576.5 Million Arbitration Hit

Lytix Biopharma Calls April AGM and Proposes No 2025 Dividend

Argent Biopharma Issues 2.5 Million Unquoted Performance Rights Under Incentive Scheme

07:00 ETLakeShore Biopharma Announces Receipt of Buyer Group Notice and Postponement of Extraordinary General Meeting of Shareholders

Lytix Biopharma Wins Shareholder Backing for NOK 30m Offering and Conversion to Public Company